More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

Neuren FDA meeting confirms Phase 3 plan for Rett syndrome

Oct 12, 2017 at 10:20 PM EDT · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Oct 12, 2017 at 10:20 PM EDT · 1 page · English

On 6ix: 6ix.com/news/neuren-fda-meeting-confirms-phase-3-plan-for-rett-syndrome

Neuren Pharmaceuticals Limited on 6ix

Story so far

  • Presentations and publication for Rett syndrome trialsOct 5, 2017
  • Neuren granted Type B Meeting with FDA for Rett syndromeJul 20, 2017
  • Neuren Pharmaceuticals granted Type B Meeting with FDA for Rett syndromeJul 20, 2017

Earlier from Neuren Pharmaceuticals

  • Presentations and publication for Rett syndrome trialsOct 4, 2017
  • Change of Director's Interest NoticeAug 29, 2017
  • Notice under section 708A(5)(e) of the Corporations ActAug 29, 2017
  • Results of MeetingAug 28, 2017
  • Neuren Pharmaceuticals reports 2017 half-year resultsAug 24, 2017

Later from Neuren Pharmaceuticals

  • Consolidation/Split - NEUNov 16, 2017
  • Neuren announces new US patent to be granted for NNZ-2591Dec 5, 2017
  • Preliminary Final ReportFeb 28, 2018
  • S&P DJ Indices Announces March Quarterly RebalanceMar 8, 2018
  • Disclosure under Listing Rule 4.3DMar 29, 2018
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer